European go-ahead for Schering's Angeliq
The EU has positively concluded the Mutual Recognition Procedure (MRP) for Schering's novel low dose hormone replacement therapy product Angeliq, paving the way for a pan European launch this autumn.
The EU has positively concluded the Mutual Recognition Procedure (MRP) for Schering's novel low dose hormone replacement therapy product Angeliq, paving the way for a pan European launch this autumn.
Schering received the first European approval for Angeliq in December 2002 in the Netherlands, which served as the reference member state for the MRP.
Angeliq is a low-dose combination preparation and the only HRT product which combines estradiol with progestin drospirenone, developed by Schering. Drospirenone's pharmacological profile mimics the hormone progesterone, and counteracts water retention that estrogen and many synthetic progestins can cause by inhibiting the effect of aldosterone, the adrenal cortical hormone that regulates the body's sodium and water balance.